tiprankstipranks

Kineta initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Robert Burns initiated coverage of Kineta with a Buy rating and $8 price target. Kineta is a clinical-stage biotechnology company focused on developing next generation immuno-oncology medicines, with principal emphasis on the VISTA and CD27 targets, the analyst tells investors in a research note. The firm says Kineta’s assets are aimed at addressing immunosuppression and T-cell exhaustion, which plays a key role in determining the impact of immune system activation against tumor cells.

Confident Investing Starts Here:

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on KA:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue